{"id":"W2902378590","doi":"10.1002/cncr.31891","title":"Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies","year":2018,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"Ignyta; Chugai Pharmaceutical; Novartis Pharma; Genentech; Ono Pharmaceutical; Loxo Oncology; Astellas Pharma; Yuhan; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Clovis Oncology; Ariad Pharmaceuticals; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; T790M; Osimertinib; Internal medicine; Discontinuation; Lung cancer; Clinical endpoint; Hazard ratio; Confidence interval; Gastroenterology; Surgery; Oncology; Cancer; Clinical trial; Epidermal growth factor receptor; Gefitinib; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003523792,0.0002258034,0.0006545492,0.0002857906,0.00007833898,0.000009617545,0.0000765466,0.00005345218,0.0003455014],"category_scores_gemma":[0.00001826706,0.0001717737,0.0001213156,0.0009386779,0.0001187369,0.0001233745,0.0000256016,0.0000841336,0.000002940475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005386579,"about_ca_system_score_gemma":0.0003354953,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001930432,"about_ca_topic_score_gemma":0.005674732,"domain_scores_codex":[0.9986863,0.00002789276,0.0003682015,0.0004111446,0.0002486791,0.0002577447],"domain_scores_gemma":[0.9986383,0.00006318843,0.0002728832,0.0002794706,0.0006377691,0.0001084405],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001881846,0.0006904053,0.9605845,0.00009405107,0.01069872,0.00002178833,0.008111274,0.0003332412,0.0007668479,0.000001143093,0.0001915805,0.01662461],"study_design_scores_gemma":[0.02500593,0.0008039278,0.9419562,0.0006215024,0.01986984,1.204445e-7,0.0003771817,0.0006038095,0.01051806,0.000003497084,0.00003004272,0.0002099145],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917787,0.005571837,0.0002581156,0.0001159154,0.0002886763,0.0009559641,0.0007429831,0.00002154257,0.0002662263],"genre_scores_gemma":[0.9973067,0.0002654711,0.0003660542,0.0002995325,0.00008994747,0.0004623756,0.0004764413,0.00003011983,0.0007033725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02312408,"threshold_uncertainty_score":0.7004727,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01175999927836135,"score_gpt":0.3536241179805094,"score_spread":0.3418641187021481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}